3M Surges 94% Amid Dow's Market Challenges

In 2025, Amgen Inc. has emerged as a leading performer in the Dow Jones Industrial Average, achieving a year-to-date stock increase of over 12%. The company is innovating in healthcare with key products such as Repatha for cholesterol management and the new weight-loss drug MariTide, alongside a strategic acquisition of Horizon that enhances its market position. Meanwhile, 3M Company has seen an impressive stock surge of 94% over the past year, attributed to operational reforms under new CEO William Brown, who focuses on innovation and profitability. 3M's revenue reached $6 billion in the last quarter, highlighting its resilience amid market fluctuations. Analysts, including Andrew Obin from BofA, have raised their price targets for 3M, reflecting strong confidence in its strategic direction. Both companies underscore the ongoing appeal of stable blue-chip stocks in a volatile market landscape.